Clinical Trials

Inclusion Criteria:

- Documented diagnosis of ATTR amyloidosis with cardiomyopathy

- Medical history of heart failure (HF)

- Symptoms of HF are optimally managed and clinically stable within 28 days prior to
administration of study intervention

- Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 1000
pg/mL (or greater than or equal to 2000 pg/mL if participant has known atrial
fibrillation)

Exclusion Criteria:

- New York Heart Association (NYHA) Class IV HF

- Polyneuropathy Disability score of IV (confined to wheelchair or bed)

- Has hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection

- History of active malignancy within 3 years prior to screening

- RNA silencer therapy (patisiran, inotersen and/or eplontersen) within 12 months prior
to dosing. Any prior vutrisiran use is not allowed

- Initiation of tafamidis within 6 months prior to study dosing

- Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2

- Liver failure

- Uncontrolled blood pressure

- Unable or unwilling to take vitamin A supplementation for the duration of the study

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/14/23. Questions regarding updates should be directed to the study team contact.